Kadans Science Partner has added Windrush Court in Oxford, UK to its Pan-European portfolio. The asset was acquired from Oxford Biomedica in a sale and leaseback transaction. With the acquisition of this 75,000ft² building, the Kadans portfolio now consists of over 50 buildings and numerous projects under development in the Netherlands, United Kingdom, Germany, Belgium, France, and Spain.
James Sheppard, Managing Director (UK & Ireland) said: ‘We are delighted to secure this tremendously important asset in the Oxford ecosystem. Oxford Biomedica is one of the world’s leading companies in cell & gene therapy, an area of deep specialism for Kadans, and we look forward to building a relationship with the team.’
Stuart Paynter, Chief Financial Officer of Oxford Biomedica, commented: “We are pleased to have exchanged contracts for the sale and leaseback of our state-of-the-art Windrush Court facility, and look forward to building a relationship with Kadans, the European leader in the development and management of life sciences buildings and ecosystems. The proceeds of the transaction will enhance our net cash position, providing us with additional financial flexibility as we build our leadership as an innovation-led CDMO across all viral vectors for cell and gene therapy.”
Andrew Lockhart, Senior Director of CBRE Oxford office and Life Sciences Division commented: ‘We are delighted to have advised Oxford Biomedica in the sale of Windrush Court to Kadans. It represents a highlight in the Oxford property market and the strength of the Life Sciences sector, which will allow both Oxford Biomedica and Kadans to strength their relative positions in this exciting and growth market’.
Freddie Owen, Partner at Knight Frank, commented: ‘Knight Frank are delighted to have advised Kadans on the acquisition of Oxford Biomedica’s Headquarters. Windrush Court is a high quality life science laboratory & office facility and a great addition to the existing Kadans portfolio.’